kff employer health benefits survey 2025 glp-1 coverage In 2025: Family Premiums Rise 6 Percent, Large Employers Increase Of GLP-1s For Weight Loss Employer Health Benefit Survey |

President Donald Trump has also pushed for lower drug prices, and a November deal with the administration slashed GLP-1 prices in the country

I dont fully register that all the time until I see comments, of course

But the real future of obesity medicine may not simply be stronger drugs. It may be personalized metabolic treatment based on: patient profile muscle mass inflammation markers insulin resistance long-term sustainability The era of precision metabolic medicine is only beginning

By contrast, some rivals have struggled with supply or slower clinical rollout

A practical sequence is metabolic optimization on therapy planned discontinuation label-informed washout post-discontinuation weight/metabolic stabilization conception attempt or ART

SOLIQUA [soh LEE kwa] combines lixisenatide with insulin glargine (Lantus)